Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

dr b
Videos
Daniel Brown, MD, FSIR, Highlights the Role of Liver-Directed Therapy in Cholangiocarcinoma
03/26/2022
In a debate at the 2022 Great Debates and Updates in Gastrointestinal Malignancies meeting, Daniel Brown, MD, FSIR, Vanderbilt University Medical Center, argued in favor of liver-directed therapy for patients with cholangiocarcinoma.
In a debate at the 2022 Great Debates and Updates in Gastrointestinal Malignancies meeting, Daniel Brown, MD, FSIR, Vanderbilt University Medical Center, argued in favor of liver-directed therapy for patients with cholangiocarcinoma.
In a debate at the 2022 Great...
03/26/2022
Oncology
dr s
Videos
The Nonoperative Management of Rectal Cancer
03/26/2022
J. Joshua Smith, MD, PhD, FACS, Memorial Sloan Kettering Cancer Center, highlights the nonoperative management of rectal cancer.
J. Joshua Smith, MD, PhD, FACS, Memorial Sloan Kettering Cancer Center, highlights the nonoperative management of rectal cancer.
J. Joshua Smith, MD, PhD, FACS,...
03/26/2022
Oncology
dr smith
Videos
Dr Smith Reviews Short-Course Radiation Therapy in Rectal Cancer
03/26/2022
J. Joshua Smith, MD, PhD, FACS, Memorial Sloan Kettering Cancer Center, discusses short-course vs long-course radiation therapy in rectal cancer, presented at the 2022 GDI GI Meeting.
J. Joshua Smith, MD, PhD, FACS, Memorial Sloan Kettering Cancer Center, discusses short-course vs long-course radiation therapy in rectal cancer, presented at the 2022 GDI GI Meeting.
J. Joshua Smith, MD, PhD, FACS,...
03/26/2022
Oncology

Advertisement

Dr V
Videos
Dr Vijayvergia Discusses the Role of HIPEC in CRS
03/26/2022
Namrata Vijayvergia, MD, FACP, Fox Chase Cancer Center, discusses whether or not the role for HIPEC is necessary for cytoreductive surgery, a debate presented at the 2022 Great Debates and Updates in Gastrointestinal Malignancies.
Namrata Vijayvergia, MD, FACP, Fox Chase Cancer Center, discusses whether or not the role for HIPEC is necessary for cytoreductive surgery, a debate presented at the 2022 Great Debates and Updates in Gastrointestinal Malignancies.
Namrata Vijayvergia, MD, FACP,...
03/26/2022
Oncology
Dr V
Videos
Systematic Therapy Approach Following Metastatic Resection Featuring Dr Vijayvergia
03/25/2022
Namrata Vijayvergia, MD, Fox Chase Cancer Center, discusses standard observation in systematic therapy following metastatic resection, a debate presented at the 2022 GDU GI Annual Meeting.
Namrata Vijayvergia, MD, Fox Chase Cancer Center, discusses standard observation in systematic therapy following metastatic resection, a debate presented at the 2022 GDU GI Annual Meeting.
Namrata Vijayvergia, MD, Fox...
03/25/2022
Oncology
Craig Portell, MD, University of Virginia Health
Videos
Frontline Venetoclax Plus Obinutuzimab and Bendamustine for Patients With High Tumor Burden FL
03/23/2022
Craig A Portell, MD, talks about a phase 2 study of venetoclax in combination with obinutuzumab and bendamustine for patients with high tumor burden FL as frontline therapy.
Craig A Portell, MD, talks about a phase 2 study of venetoclax in combination with obinutuzumab and bendamustine for patients with high tumor burden FL as frontline therapy.
Craig A Portell, MD, talks about...
03/23/2022
Oncology

Advertisement

Dr Mesa
Videos
Ruben Mesa, MD, Discusses Momelotinib in Patients With Myelofibrosis
03/16/2022
Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.
Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.
Ruben Mesa, MD, discusses the...
03/16/2022
Oncology
Dr Gale
Videos
Dr Gale Highlights Transplants, Cell Therapies for CLL
03/14/2022
Robert Peter Gale, MD, PhD, DSc (Hon), FACP, FRCP, FRSM, highlights transplants and cell therapies, including HCT and CAR T-cells, for patients with CLL.
Robert Peter Gale, MD, PhD, DSc (Hon), FACP, FRCP, FRSM, highlights transplants and cell therapies, including HCT and CAR T-cells, for patients with CLL.
Robert Peter Gale, MD, PhD, DSc...
03/14/2022
Oncology
Dr Burger
Videos
Dr Burger Overviews the Activation, Expansion of T Follicular Helper Cells in CLL
03/10/2022
Jan A. Burger, MD, PhD, highlights a study on the activation and expansion of T follicular helper cells in co-cultures of patients with CLL.
Jan A. Burger, MD, PhD, highlights a study on the activation and expansion of T follicular helper cells in co-cultures of patients with CLL.
Jan A. Burger, MD, PhD,...
03/10/2022
Oncology

Advertisement

Dr Uy
Videos
Dr Uy Reviews Low-Dose CPX-351 Plus Venetoclax for AML
03/09/2022
Geoffrey L. Uy, MD, reviews the safety and efficacy results from a phase 1b study on lower-dose CPX-351 plus venetoclax as a first-line treatment for patients with AML who are unfit for intensive chemotherapy, presented at ASH 2021.
Geoffrey L. Uy, MD, reviews the safety and efficacy results from a phase 1b study on lower-dose CPX-351 plus venetoclax as a first-line treatment for patients with AML who are unfit for intensive chemotherapy, presented at ASH 2021.
Geoffrey L. Uy, MD, reviews the...
03/09/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use